


WHAT IS CLAIMED IS:


1. A compound of formula (I):



5 wherein:

R<sup>1</sup> is selected from the group consisting of:

- (1) -C<sub>1-6</sub>alkyl,  
 (2) -C<sub>2-6</sub> alkenyl,  
 10 (3) -C<sub>0-6</sub>alkyl-C<sub>3-6</sub> cycloalkyl,  
 (4)



- (5) heteroaryl selected from the group consisting of furyl, pyranyl, benzofuranyl,  
 15 isobenzofuranyl, chromenyl, thienyl, benzothiophenyl, pyrrolyl, pyrazolyl, imidazolyl,  
 pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, quinolyl  
 and isoquinolyl,

wherein

- (a) said alkyl, alkenyl or cycloalkyl is unsubstituted or substituted with  
 20 one or more halogen, -C<sub>1-6</sub>alkyl, -C<sub>1-6</sub>alkoxy, hydroxy or cyano, and  
 (b) said heteroaryl is unsubstituted or substituted with one or  
 more halogen, -C<sub>1-6</sub>alkyl, -C<sub>1-6</sub>alkoxy, phenyl, hydroxy or cyano,

and wherein R<sup>1a</sup>, R<sup>1b</sup>, R<sup>1c</sup>, R<sup>1d</sup> and R<sup>1e</sup> are selected from the group consisting of:

- (a) hydrogen,  
 25 (b) halogen,

(c) cyano,

(d) hydroxyl,

(e)  $-C_{1-6}$  alkoxy,

(f)  $-C(=O)-O-R^{7a}$ ,

5 (g)  $-O-C_{0-6}alkyl-C(=O)-R^{7a}$ ,

(h)  $-N-R^{7a}-S(O)_p-R^{7b}$ ,

or  $R^{1b}$  and  $R^{1c}$  are linked together to form  $-O-CH_2-O-$  or  $-CH=CH-CH=CH-$ ;

wherein said aryl is unsubstituted or substituted with one or more halogen,  $-C_{1-6}alkyl$ ,  $-C_{1-6}alkoxy$ , hydroxyl or cyano;

10

$R^2$  is selected from the group consisting of:

(1) hydrogen,

(2) halogen,

(3)  $-C_{0-6}alkyl-Q^1-C_{1-6}alkyl$ , wherein  $Q^1$  is O or S,

15 (4)  $-C_{1-6}alkyl$ , and

(5) hydroxyl;

$R^3$  is selected from the group consisting of:


(1) hydrogen,

20 (2)  $-C_{1-6}alkyl$ ,

(3)  $-C_{0-6}alkyl-C_{3-6}cycloalkyl$ ,

(4)  $-C_{0-6}alkyl-Q^2-C_{1-6}alkyl$ , wherein  $Q^2$  is O, S or  $-C(=O)-O-$ , and

(5)



25

(6)  $-CH_2$ -heteroaryl, wherein said heteroaryl is selected from the group consisting of furyl, pyranlyl, benzofuranyl, isobenzofuranyl, chromenyl, thienyl, benzothiophenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, quinolyl and isoquinolyl,

wherein said alkyl or cycloalkyl is unsubstituted or substituted with one or more

30

(a) halogen,

- (b)  $-C_{1-6}$ alkyl,
- (c)  $-C_{2-6}$ alkenyl,
- (d)  $-C_{1-6}$ alkoxy,
- (e)  $-C_{6-10}$  aryl,
- (f) hydroxyl, or
- (g) cyano,

and said heteroaryl is unsubstituted or substituted with one or more

- (a)  $-C_{1-6}$ alkyl,
- (b)  $-NR^{3f}R^{3g}$ , wherein  $R^{3f}$  and  $R^{3g}$  are selected from the group consisting of:

- (i) hydrogen,
- (ii)  $-C_{1-6}$  alkyl,
- (iii)  $-C_{1-6}$ alkyl- $-C_{6-10}$  aryl, wherein said aryl can be substituted or unsubstituted with halogen, cyano,  $C_{1-6}$  alkyl or  $C_{1-6}$  alkoxy, or
- (iv)  $-C_{1-6}$ alkyl- $-NR^{7a}R^{7b}$ ,

or N,  $R^{3f}$  and  $R^{3g}$  together form a 5 or 6 membered heterocyclic group, optionally containing an N, S or O atom in addition to the N atom attached to  $R^{3f}$  and  $R^{3g}$ ;

and  $R^{3a}$ ,  $R^{3b}$ ,  $R^{3c}$ ,  $R^{3d}$  and  $R^{3e}$  are selected from the group consisting of:

- (i) hydrogen,
- (ii) halogen,
- (iii) cyano,
- (iv) hydroxyl,
- (v)  $-C_{1-6}$  alkyl,
- (vi)  $-O-R^{7a}$ ,
- (vii)  $-(C=O)-O-R^8$ ,
- (viii)  $-NR^{7a}-S(O)_p OR^{7b}$ ,
- (ix)  $-NR^{7a}-S(O)_p R^{7b}$ ,
- (x)  $-C_{0-6}$ alkyl  $-S(O)_m R^{7a}$ ,
- (xi)  $-C(=O)-NR^{7a}R^{7b}$ ,

(xii)  $-\text{C}(=\text{O})-\text{R}^8$

(xiii)  $-\text{NH}-\text{C}(=\text{O})-\text{R}^{7a}$ ,

(xiv)  $-\text{C}_{0-6}\text{alkyl}-\text{NR}^{7a}\text{R}^{7b}$ ,

(xv)  $-\text{N}_3$ ,

(xvi)  $-\text{NO}_2$ ,

(xvii)  $\text{C}_{6-10}$  aryl, wherein said aryl can be unsubstituted or substituted with one or more

(A) halogen,

(B) cyano,

(C)  $-\text{C}_{1-6}$  alkyl,

(D)  $-\text{C}_{1-6}$  alkoxy,

(E)  $-\text{C}(=\text{O})-\text{O}-\text{R}^{7a}$ ,

(F)  $-\text{C}(=\text{O})-\text{R}^{7a}$ ,

(G)  $-\text{NR}^{7a}\text{R}^{7b}$ ,

(H)  $-\text{NR}^{7a}-\text{S}(\text{O})_p-\text{R}^{7b}$ ,

(I)  $-\text{NR}^{7a}-\text{C}(=\text{O})-\text{R}^{7b}$ ,

(J)  $-\text{NO}_2$

(xviii) heteroaryl selected from the group consisting of furyl, pyranlyl, benzofuranyl, isobenzofuranyl, chromenyl, thienyl, benzothiophenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, quinolyl and isoquinolyl,

wherein said heteroaryl is unsubstituted or substituted with one or more

(A)  $-\text{C}_{1-6}$  alkyl, or

(B)  $-\text{C}_{1-6}$  alkoxy;

or  $\text{R}^{3c}$  and  $\text{R}^{3d}$  are linked together to form phenyl or the group  $-\text{O}-\text{CH}_2-\text{O}-$  or  $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$ ;

or  $\text{R}^2$  and  $\text{R}^3$  are linked to form a carbocyclic ring (A):



wherein  $\text{Q}^3$  is selected from the group consisting of:

- (1)  $-\text{CR}^7\text{aR}^7\text{b}-$ ,  
 (2)  $-\text{CR}^7\text{aR}^7\text{bCR}^7\text{cR}^7\text{d}-$ ,  
 (3)  $-\text{CR}^7\text{a}=\text{CR}^7\text{b}-$ ,  
 (4)  $-\text{CR}^7\text{aR}^7\text{bCR}^7\text{cR}^7\text{dCR}^7\text{eR}^7\text{f}-$ ,  
 (5)  $-\text{CR}^7\text{a}=\text{CR}^7\text{bCR}^7\text{cR}^7\text{d}-$ , and  
 (6)  $-\text{CR}^7\text{aR}^7\text{bCR}^7\text{d}=\text{CR}^7\text{e}-$ ;

$\text{R}^4$  is selected from the group consisting of:


- (1) hydrogen,  
 (2) halogen,  
 (3)  $-\text{C}_{1-6}\text{alkyl}$ ,  
 (4)  $-\text{C}_{2-6}\text{alkenyl}$ ,  
 (5)  $-\text{C}_{2-6}\text{alkynyl}$ ,  
 (6) phenyl,  
 (7) benzyl, and  
 (8) heteroaryl selected from the group consisting of furyl, pyranlyl, benzofuranyl, isobenzofuranyl, chromenyl, thienyl, benzothiophenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, quinolyl and isoquinolyl,  
 wherein said alkyl, alkenyl, alkynyl and phenyl is unsubstituted or substituted with one or more  
 (a) halogen,  
 (b) cyano,  
 (c) hydroxyl,  
 (d) phenyl,  
 (e)  $-\text{C}_{1-6}\text{ alkyl}$ ,  
 (f)  $-\text{C}_{1-6}\text{ alkoxy}$ ,  
 (g)  $-\text{C}(=\text{O})-\text{O}-\text{R}^7\text{a}$ ,  
 (h)  $-\text{C}(=\text{O})-\text{R}^7\text{a}$ ,  
 (i)  $-\text{NR}^7\text{aR}^7\text{b}$ ,  
 (j)  $-\text{NR}^7\text{a}-\text{S}(\text{O})_p-\text{R}^7\text{b}$ ,  
 (k)  $-\text{NR}^7\text{a}-\text{C}(=\text{O})-\text{R}^7\text{b}$ ,  
 (l)  $-\text{NO}_2$ ;

and said heteroaryl is unsubstituted or substituted with one or more:

- (a)  $-C_{1-6}$ alkyl,  
 (b)  $-C(=O) -O-R^{7a}$   
 (c)  $-C(=O) -R^{7a}$   
 (d)  $-NR^{3f}R^{3g}$ , wherein  $R^{3f}$  and  $R^{3g}$  selected from the group  
 consisting of


- (i) hydrogen,  
 (ii)  $-C_{1-6}$  alkyl,  
 (iii)  $-C_{1-6}$ alkyl- $C_{6-10}$  aryl, wherein said aryl can be  
 substituted or unsubstituted with halogen, cyano,  $C_{1-6}$  alkyl or  
 $C_{1-6}$  alkoxy, or  
 (iv)  $-C_{1-6}$ alkyl- $NR^{7a}R^{7b}$  ;

or  $R^3$  and  $R^4$  may be joined together to form a 6-membered carbocyclic ring (B):



- 15 provided that when  $R^3$  and  $R^4$  are joined together to form (B) then  $R^1$  and  $R^2$  are selected from the group consisting of hydrogen or  $C_{1-6}$  alkyl, and  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$  and  $X^6$  are selected from the group consisting of hydrogen,  $C_{1-6}$  alkyl,  $C_{3-6}$  cycloalkyl, cyano, alkylaryl or phenyl,

or  $R^3$  and  $R^4$  may be joined together to form a 7-membered carbocyclic ring (C):



- 20 provided that when  $R^3$  and  $R^4$  are joined together to form (C) then  $R^1$  and  $R^2$  are selected from the group consisting of hydrogen,  $C_{1-6}$  alkyl or phenyl, or  $R^1$  and  $R^2$  can be linked together by the group –  
 25  $CH_2CH_2CH_2CH_2-$ ; and  $Y^1$ ,  $Y^2$ ,  $Y^3$ ,  $Y^4$ ,  $Y^5$ ,  $Y^6$ ,  $Y^7$  and  $Y^8$  are selected from the group consisting of hydrogen,  $C_{1-6}$  alkyl,  $C_{3-6}$  cycloalkyl, cyano, alkylaryl or phenyl,

or R<sup>1</sup> and Y<sup>5</sup>, or R<sup>1</sup> and Y<sup>7</sup>, are linked together by –CH<sub>2</sub>–,

or R<sup>1</sup> and Y<sup>1</sup>, or Y<sup>1</sup> and Y<sup>3</sup>, are linked together to form a phenyl or cyclopentyl ring;

R<sup>7a</sup>, R<sup>7b</sup>, R<sup>7c</sup>, R<sup>7d</sup>, R<sup>7e</sup> and R<sup>7f</sup> are selected from the group consisting of:

- (1) hydrogen,
- (2) C<sub>1-6</sub> alkyl, and
- (3) C<sub>6-10</sub> aryl;

wherein said alkyl or aryl is unsubstituted or substituted with one or more halogen, –C<sub>1-6</sub>alkyl, –C<sub>1-6</sub>alkoxy, hydroxyl or cyano;

R<sup>8</sup> is selected from the group consisting of:

- (1) hydrogen,
- (2) C<sub>1-6</sub> alkyl, and
- (3) C<sub>6-10</sub> aryl, wherein said aryl is unsubstituted or substituted with one or more halogen, –C<sub>1-6</sub>alkyl, –C<sub>1-6</sub>alkoxy, hydroxy or cyano;

n is 0, 1, 2 or 3


m is 0 or 1;

p is 1 or 2;

and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof.

2. The compound of Claim 1 wherein R<sup>3</sup> is selected from the group consisting of:


- (1) –C<sub>1-6</sub>alkyl,
- (2) –C<sub>0-6</sub>alkyl–C<sub>3-6</sub>cycloalkyl,
- (3)



- (4)  $-\text{CH}_2$ -heteroaryl, wherein said heteroaryl is selected from the group consisting of furyl, pyranyl, benzofuranyl, isobenzofuranyl, chromenyl, thienyl, benzothiophenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, quinolyl and isoquinolyl.

5


3. The compound of Claim 2 wherein  $\text{R}^3$  is



and  $n$  is 1.

10

4. The compound of Claim 2 wherein  $\text{R}^1$  is



and  $m$  is 0.

15


5. The compound of Claim 4 wherein  $\text{R}^{1a}$ ,  $\text{R}^{1b}$ ,  $\text{R}^{1d}$  and  $\text{R}^{1e}$  are hydrogen, and  $\text{R}^{1c}$  is selected from the group consisting of halogen,  $\text{C}_{1-6}$  alkyl and  $\text{C}_{1-6}$  alkoxy.

6. The compound of Claim 2 wherein  $\text{R}^2$  is hydrogen.


20

7. The compound of Claim 2 wherein  $\text{R}^4$  is hydrogen.

8. The compound of Claim 1 which is a compound of formula (III)



9. The compound of Claim 8 wherein R<sup>1</sup> is



5

and m is 0.


10. The compound of Claim 9 wherein Q<sup>3</sup> is selected from the group consisting of  
 (1) -CR<sup>7a</sup>R<sup>7b</sup>-,  
 (2) -CR<sup>7a</sup>R<sup>7b</sup>CR<sup>7c</sup>R<sup>7d</sup>-, and  
 (3) -CR<sup>7a</sup>R<sup>7b</sup>CR<sup>7c</sup>R<sup>7d</sup>CR<sup>7e</sup>R<sup>7f</sup>-.  
 10

11. The compound of Claim 10 wherein R<sup>1d</sup> is selected from the group consisting of  
 15 halogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy and cyano, and R<sup>1a</sup>, R<sup>1b</sup>, R<sup>1c</sup> and R<sup>1e</sup> are hydrogen.

12. The compound of Claim 9 wherein R<sup>1b</sup> and R<sup>1d</sup> are selected from the group  
 consisting of halogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy and cyano, and R<sup>1a</sup>, R<sup>1c</sup> and R<sup>1e</sup> are hydrogen.


13. The compound of Claim 8 wherein Q<sup>3</sup> is selected from the group consisting of  
 20 -CH<sub>2</sub>CH<sub>2</sub>- and -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-.

14. The compound of Claim 1 which is a compound of formula (IV)





(IV)






15. The compound of Claim 14 wherein R<sup>1</sup> and R<sup>2</sup> are hydrogen.
16. The compound of Claim 1 which is a compound of formula (V)



(V)

17. The compound of Claim 1 which is selected from the group consisting of






5

and pharmaceutically acceptable salts thereof.


18. The compound of Claim 1 which is selected from the group consisting of

PCT/US2005/010224  
Example Structure


8




9




10




11




12




13




14




15




16



17




18




Example

Structure


19




20




21




22




23




24




25




26




27




28




29




30




31




32




33




34




35




36




37




38



39




40




## Structure

C1CCC(CC1)(c2ccc(F)cc2)c3nc([NH3+])cs3C1CCC(CC1)(c2ccccc2F)c3cc[nH+]3CCCC1=C(C2=CC=CC=C2Cl)C3=NC(=S1)NNc1nc(s1)C(c2ccccc2)C3(CCCC3)c4ccc(Cl)cc4NC1=NC=C(C=C1)CC(C2=CC=CC=C2I)C=CC1=CC=C2C(=C1)CCCC2C3=CN(C(=S3)N)NC1=CC=C2C(=C1)C(=CC=C2)C3=CC=CC=C3C4=CC=CC=C4C5=CC=CC=C5C6=CC=CC=C6C7=CC=CC=C7C8=CC=CC=C8C9=CC=CC=C9C10=CC=CC=C10C11=CC=CC=C11C12=CC=CC=C12C13=CC=CC=C13C14=CC=CC=C14C15=CC=CC=C15C16=CC=CC=C16C17=CC=CC=C17C18=CC=CC=C18C19=CC=CC=C19C20=CC=CC=C20C21=CC=CC=C21C22=CC=CC=C22C23=CC=CC=C23C24=CC=CC=C24C25=CC=CC=C25C26=CC=CC=C26C27=CC=CC=C27C28=CC=CC=C28C29=CC=CC=C29C30=CC=CC=C30C31=CC=CC=C31C32=CC=CC=C32C33=CC=CC=C33C34=CC=CC=C34C35=CC=CC=C35C36=CC=CC=C36C37=CC=CC=C37C38=CC=CC=C38C39=CC=CC=C39C40=CC=CC=C40C41=CC=CC=C41C42=CC=CC=C42C43=CC=CC=C43C44=CC=CC=C44C45=CC=CC=C45C46=CC=CC=C46C47=CC=CC=C47C48=CC=CC=C48C49=CC=CC=C49C50=CC=CC=C50C51=CC=CC=C51C52=CC=CC=C52C53=CC=CC=C53C54=CC=CC=C54C55=CC=CC=C55C56=CC=CC=C56C57=CC=CC=C57C58=CC=CC=C58C59=CC=CC=C59C60=CC=CC=C60C61=CC=CC=C61C62=CC=CC=C62C63=CC=CC=C63C64=CC=CC=C64C65=CC=CC=C65C66=CC=CC=C66C67=CC=CC=C67C68=CC=CC=C68C69=CC=CC=C69C70=CC=CC=C70C71=CC=CC=C71C72=CC=CC=C72C73=CC=CC=C73C74=CC=CC=C74C75=CC=CC=C75C76=CC=CC=C76C77=CC=CC=C77C78=CC=CC=C78C79=CC=CC=C79C80=CC=CC=C80C81=CC=CC=C81C82=CC=CC=C82C83=CC=CC=C83C84=CC=CC=C84C85=CC=CC=C85C86=CC=CC=C86C87=CC=CC=C87C88=CC=CC=C88C89=CC=CC=C89C90=CC=CC=C90C91=CC=CC=C91C92=CC=CC=C92C93=CC=CC=C93C94=CC=CC=C94C95=CC=CC=C95C96=CC=CC=C96C97=CC=CC=C97C98=CC=CC=C98C99=CC=CC=C99C100=CC=CC=C100C101=CC=CC=C101C102=CC=CC=C102C103=CC=CC=C103C104=CC=CC=C104C105=CC=CC=C105C106=CC=CC=C106C107=CC=CC=C107C108=CC=CC=C108C109=CC=CC=C109C110=CC=CC=C110C111=CC=CC=C111C112=CC=CC=C112C113=CC=CC=C113C114=CC=CC=C114C115=CC=CC=C115C116=CC=CC=C116C117=CC=CC=C117C118=CC=CC=C118C119=CC=CC=C119C120=CC=CC=C120C121=CC=CC=C121C122=CC=CC=C122C123=CC=CC=C123C124=CC=CC=C124C125=CC=CC=C125C126=CC=CC=C126C127=CC=CC=C127C128=CC=CC=C128C129=CC=CC=C129C130=CC=CC=C130C131=CC=CC=C131C132=CC=CC=C132C133=CC=CC=C133C134=CC=CC=C134C135=CC=CC=C135C136=CC=CC=C136C137=CC=CC=C137C138=CC=CC=C138C139=CC=CC=C139C140=CC=CC=C140C141=CC=CC=C141C142=CC=CC=C142C143=CC=CC=C143C144=CC=CC=C144C145=CC=CC=C145C146=CC=CC=C146C147=CC=CC=C147C148=CC=CC=C148C149=CC=CC=C149C150=CC=CC=C150C151=CC=CC=C151C152=CC=CC=C152C153=CC=CC=C153C154=CC=CC=C154C155=CC=CC=C155C156=CC=CC=C156C157=CC=CC=C157C158=CC=CC=C158C159=CC=CC=C159C160=CC=CC=C160C161=CC=CC=C161C162=CC=CC=C162C163=CC=CC=C163C164=CC=CC=C164C165=CC=CC=C165C166=CC=CC=C166C167=CC=CC=C167C168=CC=CC=C168C169=CC=CC=C169C170=CC=CC=C170C171=CC=CC=C171C172=CC=CC=C172C173=CC=CC=C173C174=CC=CC=C174C175=CC=CC=C175C176=CC=CC=C176C177=CC=CC=C177C178=CC=CC=C178C179=CC=CC=C179C180=CC=CC=C180C181=CC=CC=C181C182=CC=CC=C182C183=CC=CC=C183C184=CC=CC=C184C185=CC=CC=C185C186=CC=CC=C186C187=CC=CC=C187C188=CC=CC=C188C189=CC=CC=C189C190=CC=CC=C190C191=CC=CC=C191C192=CC=CC=C192C193=CC=CC=C193C194=CC=CC=C194C195=CC=CC=C195C196=CC=CC=C196C197=CC=CC=C197C198=CC=CC=C198C199=CC=CC=C199C200=CC=CC=C200C201=CC=CC=C201C202=CC=CC=C202C203=CC=CC=C203C204=CC=CC=C204C205=CC=CC=C205C206=CC=CC=C206C207=CC=CC=C207C208=CC=CC=C208C209=CC=CC=C209C210=CC=CC=C210C211=CC=CC=C211C212=CC=CC=C212C213=CC=CC=C213C214=CC=CC=C214C215=CC=CC=C215C216=CC=CC=C216C217=CC=CC=C217C218=CC=CC=C218C219=CC=CC=C219C220=CC=CC=C220C221=CC=CC=C221C222=CC=CC=C222C223=CC=CC=C223C224=CC=CC=C224C225=CC=CC=C225C226=CC=CC=C226C227=CC=CC=C227C228=CC=CC=C228C229=CC=CC=C229C230=CC=CC=C230C231=CC=CC=C231C232=CC=CC=C232C233=CC=CC=C233C234=CC=CC=C234C235=CC=CC=C235C236=CC=CC=C236C237=CC=CC=C237C238=CC=CC=C238C239=CC=CC=C239C240=CC=CC=C240C241=CC=CC=C241C242=CC=CC=C242C243=CC=CC=C243C244=CC=CC=C244C245=CC=CC=C245C246=CC=CC=C246C247=CC=CC=C247C248=CC=CC=C248C249=CC=CC=C249C250=CC=CC=C250C251=CC=CC=C251C252=CC=CC=C252C253=CC=CC=C253C254=CC=CC=C254C255=CC=CC=C255C256=CC=CC=C256C257=CC=CC=C257C258=CC=CC=C258C259=CC=CC=C259C260=CC=CC=C260C261=CC=CC=C261C262=CC=CC=C262C263=CC=CC=C263C264=CC=CC=C264C265=CC=CC=C265C266=CC=CC=C266C267=CC=CC=C267C268=CC=CC=C268C269=CC=CC=C269C270=CC=CC=C270C271=CC=CC=C271C272=CC=CC=C272C273=CC=CC=C273C274=CC=CC=C274C275=CC=CC=C275C276=CC=CC=C276C277=CC=CC=C277C278=CC=CC=C278C279=CC=CC=C279C280=CC=CC=C280C281=CC=CC=C281C282=CC=CC=C282C283=CC=CC=C283C284=CC=CC=C284C285=CC=CC=C285C286=CC=CC=C286C287=CC=CC=C287C288=CC=CC=C288C289=CC=CC=C289C290=CC=CC=C290C291=CC=CC=C291C292=CC=CC=C292C293=CC=CC=C293C294=CC=CC=C294C295=CC=CC=C295C296=CC=CC=C296C297=CC=CC=C297C298=CC=CC=C298C299=CC=CC=C299C300=CC=CC=C300C301=CC=CC=C301C302=CC=CC=C302C303=CC=CC=C303C304=CC=CC=C304C305=CC=CC=C305C306=CC=CC=C306C307=CC=CC=C307C308=CC=CC=C308C309=CC=CC=C309C310=CC=CC=C310C311=CC=CC=C311C312=CC=CC=C312C313=CC=CC=C313C314=CC=CC=C314C315=CC=CC=C315C316=CC=CC=C316C317=CC=CC=C317C318=CC=CC=C318C319=CC=CC=C319C320=CC=CC=C320C321=CC=CC=C321C322=CC=CC=C322C323=CC=CC=C323C324=CC=CC=C324C325=CC=CC=C325C326=CC=CC=C326C327=CC=CC=C327C328=CC=CC=C328C329=CC=CC=C329C330=CC=CC=C330C331=CC=CC=C331C332=CC=CC=C332C333=CC=CC=C333C334=CC=CC=C334C335=CC=CC=C335C336=CC=CC=C336C337=CC=CC=C337C338=CC=CC=C338C339=CC=CC=C339C340=CC=CC=C340C341=CC=CC=C341C342=CC=CC=C342C343=CC=CC=C343C344=CC=CC=C344C345=CC=CC=C345C346=CC=CC=C346C347=CC=CC=C347C348=CC=CC=C348C349=CC=CC=C349C350=CC=CC=C350C351=CC=CC=C351C352=CC=CC=C352C353=CC=CC=C353C354=CC=CC=C354C355=CC=CC=C355C356=CC=CC=C356C357=CC=CC=C357C358=CC=CC=C358C359=CC=CC=C35Cc1c2ccccc2c(c1)c1cc[nH]1CSC(C1=CC=CC=C1)(C2=CC=CC=C2)c3nc(N)cs3FC(F)(F)c1ccc(cc1)C(c2ccsc2)c3cc[nH+]3Nc1nc(C2(O)(C3=CC=CC=C3)C4CCCC4)c(s1)


52




53




54




55




56




57




58




59




60




61




62




63




64




65




66




67




68




69




70




71




72




73




74




75




76




77




78




79




80




81




82



83




84




PCT/US2005/010224  
Example Structure


85




86




87




88




89




90




91




92




93



94



95




PCT/US2005/010224


Example

Structure


96




97




98




99




100




101




102




103




104



105



106




PCT/US2005/010224


Example

Structure


107




108




109




110




111




112




113




114




115



116




117




PCT/US2005/010224  
Example 118 Structure


118




119




120




121




122




123




124




125




126



127



128




## Structure


C[C@H]1[C@@H](C)[C@H](O)[C@@H]2CC[C@H]3C(=N[C@@H](S)N)C=C[C@H]123COc1ccc(cc1)[C@H](c2cc(F)c(F)cc2)c3cc[nH]3CN1C=NC(S1)C[C@H](c2ccc(OC)cc2)c3ccc(F)c(F)c3COc1ccc(cc1)C[C@H](c2cc(F)cc(F)c2)c3nc(N)s3CC(C)C(c1ccc(OC)cc1)c2nc([NH3+])cs2COc1ccc(cc1)C(Cc2ccc(OC)cc2)C3=NC(=[NH3+])S3CC(C)Oc1ccc(cc1)Cc2cc(OC)ccc2c3nc[nH+]3CCOc1ccc(cc1)Cc2cc(OC)ccc2c3nc(N)cs3CCCCOc1ccc(cc1)CC(c2ccc(OC)cc2)c3nc(N)cs3COC1=CC=C(C=C1)CC(C2=CC3=C(C=C2)OCO3)C4=NC(=[NH3+])=CS4COc1ccc(cc1)C(Cc2cc(Cl)c(Cl)cc2)c3nc(s3)N

Example 140 Structure


140




141




142




143




144




145




146




147




148



149




150




Example

Structure


151




152




153




154




155




156




157




158




159



160



161




PCT/US2005/010224


Example

Structure


162




163




164




165




166




167




168




169




170




171




172




173




174




175




176




177




178




179




180




181



182




183




PCT/US2005/010224  
Example Structure


184




185




186




187




188




189




190




191




192



193




194




PCT/US2005/010224  
Example 1 Structure


195




196




197




198




199




200




201




202




203



204




205




PCT/US2005/010224  
Example 1 Structure


206




207




208




209




210




211




212




213




214



215




216




## Example 217 Structure


217




218




219




220




221




222




223




224




225



226




227




## Example Structure


228




229




230




231




232




233




234




235




236



237




238




PCT/US2005/010224  
Example 10221 Structure


239




240




241




242




243




244




245




246




247



248




249




## Example 250 Structure


250




251




252




253




254




255




256




257




258



259




260




## Example 10224 Structure


261




262




263




264




265




266




267




268



269



270



and pharmaceutically acceptable salts thereof.

19. The pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

20. A method for treating Alzheimer's disease in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

21. A method of inhibiting HIV protease in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

22. A method of treating infection by HIV in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

23. A method of treating AIDS in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.